This is in line with previous work on cholestatic liver disease, where IL-1 signaling also was of limited importance [29] but in contrast to the choline-deficient mouse model where NASH was ameliorated by the IL-1R knockout [30]. The gene discussed is IL1A; the disease is metabolic dysfunction-associated steatohepatitis.